Skip to content
Search
Search
Home
News
CV Program
Articles by LDT
Brochures
About Us
Contact
Home
News
CV Program
Articles by LDT
Brochures
About Us
Contact
March 2023
Lou Diorio, RPh, FAPhA
David L Thomas, RPh, MBA
Trends in Regulatory Actions for 503B Compounders
Synopsis
With preparations continuing for the revised USP General Chapters related to compounding (ie, 795, 797, and 800), the evaluation phase of your organization's process should be nearing completion, if not already achieved.
View Full Article
Prev
Previous
Maximize a 503B Compounding Partnership Ask the Expert
Next
The USP Clock is Ticking on the Compounding Chapters How to accommodate State Board of Pharmacy requirements in your compliance planning
Next